Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
Part 1: Narelle Smith is joined by internationally renowned UK haematologist, Professor Gordon Cook, to discuss the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. In this episode, they explore what an AuSCT is, how the treatment process works, why it’s used, when it may not be suitable, and how best to prepare for transplant and recovery afterward.
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
